BACKGROUND: Several studies have shown that exenatide protects against ischemia-reperfusion injury and improves cardiac function in patients with acute ST-segment elevation myocardial infarction (STEMI). The effects of liraglutide, a glucagon-like peptide-1 analogue, on STEMI patients remain unclear. We planned to evaluate the effects of liraglutide on left ventricular function after primary percutaneous coronary intervention for STEMI. METHODS:A total of 92 patients were randomized 1:1 to receive either liraglutide or placebo for 7 days. Study treatment was commenced 30 minutes before intervention (1.8 mg) and maintained for 7 days after the procedure (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days). Eighty-five patients completed the trial. Transthoracic echocardiography was used to assess left ventricular function. RESULTS: At 3 months, the primary end point, a difference in change of left ventricular ejection fraction between the two groups was +4.1% (95% CI +1.1% to +6.9%) (P < .001). There was a tendency for a lower rate of no-reflow in liraglutide group that did not reach statistical significance (7% vs control group 15%, P = .20). Liraglutide could significantly improve stress hyperglycemia (P < .05). In addition, liraglutide elicited favorable changes in markers of inflammation and endothelial function. CONCLUSION: A short 7-day course of liraglutide in STEMI patients treated with primary percutaneous coronary intervention is associated with mild improvement in left ventricular ejection fraction at 3 months.
RCT Entities:
BACKGROUND: Several studies have shown that exenatide protects against ischemia-reperfusion injury and improves cardiac function in patients with acute ST-segment elevation myocardial infarction (STEMI). The effects of liraglutide, a glucagon-like peptide-1 analogue, on STEMI patients remain unclear. We planned to evaluate the effects of liraglutide on left ventricular function after primary percutaneous coronary intervention for STEMI. METHODS: A total of 92 patients were randomized 1:1 to receive either liraglutide or placebo for 7 days. Study treatment was commenced 30 minutes before intervention (1.8 mg) and maintained for 7 days after the procedure (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days). Eighty-five patients completed the trial. Transthoracic echocardiography was used to assess left ventricular function. RESULTS: At 3 months, the primary end point, a difference in change of left ventricular ejection fraction between the two groups was +4.1% (95% CI +1.1% to +6.9%) (P < .001). There was a tendency for a lower rate of no-reflow in liraglutide group that did not reach statistical significance (7% vs control group 15%, P = .20). Liraglutide could significantly improve stress hyperglycemia (P < .05). In addition, liraglutide elicited favorable changes in markers of inflammation and endothelial function. CONCLUSION: A short 7-day course of liraglutide in STEMI patients treated with primary percutaneous coronary intervention is associated with mild improvement in left ventricular ejection fraction at 3 months.
Authors: Shi Yin Wong; Ainsley Ryan Yan Bin Lee; Aaron Hon Jiun Sia; Yu Jun Wo; Yao Hao Teo; Yao Neng Teo; Nicholas L Syn; Ching-Ching Ong; Lynette L Teo; Tiong-Cheng Yeo; Kian-Keong Poh; William K Kong; Raymond C Wong; Ching-Hui Sia Journal: Cardiovasc Drugs Ther Date: 2022-07-12 Impact factor: 3.947
Authors: Bruno García Del Blanco; Imanol Otaegui; José F Rodríguez-Palomares; Antoni Bayés-Genis; Eduard Fernández-Nofrerías; Victoria Vilalta Del Olmo; Xavier Carrillo; Borja Ibáñez; Fernando Worner; Juan Casanova; Eva Pueo; Jose R González-Juanatey; Javier López-Pais; Alfredo Bardají; Gil Bonet; Mónica Fuertes; Antonio Rodríguez-Sinovas; Marisol Ruiz-Meana; Javier Inserte; Ignasi Barba; Sandra Gómez-Talavera; Gerard Martí; Bernat Serra; Neus Bellera; Manuel Ojeda-Ramos; Hug Cuellar; Filipa Valente; Maria Ángeles Carmona; Elisabet Miró-Casas; Josep R Marsal; Antonia Sambola; Rosa M Lidón; Jordi Bañeras; Jaime Elízaga; Ferran Padilla; José A Barrabés; Derek J Hausenloy; Ignacio Ferreira-González; David García-Dorado Journal: Basic Res Cardiol Date: 2021-01-25 Impact factor: 17.165
Authors: Preman Kumarathurai; Christian Anholm; Olav W Nielsen; Ole P Kristiansen; Jens Mølvig; Sten Madsbad; Steen B Haugaard; Ahmad Sajadieh Journal: Cardiovasc Diabetol Date: 2016-07-26 Impact factor: 9.951